Physician profile
Fiona Mudge
NPI 1417933888
$7,617.58
in general payments reported to CMS, 2019-2025
21 companies · $33.77 in 2025
The $33.77 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $782 · 2021: $1,546 · 2022: $1,224 · 2023: $1,798 · 2024: $1,000 · 2025: $33.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.04 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $881.16 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $813.85 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $758.33 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $570.08 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $488.09 | 2019-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $480.59 | 2019-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $472.22 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $447.17 | 2019-2022 | |
| Alkermes, INC. | $442.33 | 2021-2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $397.70 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $396.37 | 2019-2020 | |
| Corium, LLC | $151.22 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $148.10 | 2021-2023 | Aplenzin |
| Shire North American Group INC | $55.19 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $54.67 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $30.17 | 2019-2020 | |
| Tempus Ai, INC | $25.03 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.11 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $19.15 | 2025 | Qelbree |
| Biogen, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Mudge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.